Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial entities : Gilead sciences, inc. save search
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Lyndra Therapeutics Announces Positive Data from Pivotal Phase 3 Study with Oral Weekly Risperidone (LYN-005) for Schizophrenia
Published: 2024-01-04 (Crawled : 20:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.37%
H: 1.38%
C: 0.82%
lyn-005 positive schizophrenia therapeutics study
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.77%
H: 1.52%
C: 0.58%
yescarta t-cell response therapy
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
Published: 2023-12-08 (Crawled : 21:00) - prnewswire.com
ACLX | $51.67 -5.19% -5.48% 740K
|
| Email alert
Add to watchlist
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
expansion trial
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.01%
H: 0.3%
C: -0.99%
europe sciences hiv program trial
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Published: 2023-07-24 (Crawled : 00:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.02%
H: 0.45%
C: -2.71%
life hiv impact
Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.62%
H: 0.0%
C: -1.54%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.67%
H: 1.42%
C: 1.06%
update trial therapeutics
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.09%
H: 0.27%
C: -0.13%
trodelvy advantage breast cancer show
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.09%
H: 0.27%
C: -0.13%
yescarta t-cell treatment care therapy
ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower...
Published: 2023-06-03 (Crawled : 00:20) - biospace.com/
RCUS 4 | $14.59 -1.69% 0.0% 600K
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
cancer immunotherapy
Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
Published: 2023-05-09 (Crawled : 15:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -0.66%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.36%
H: 1.23%
C: 0.63%
lyn-005 schizophrenia trial therapeutics study
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
Published: 2023-04-26 (Crawled : 00:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.58%
H: 0.21%
C: -0.59%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.08%
H: 2.5%
C: 2.11%
active program
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-03-21 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: -0.48%
yescarta t-cell treatment therapy
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
tecartus t-cell leukemia trial therapy
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -8.03%
H: 0.95%
C: 0.75%
disease topline trial results
Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator
Published: 2023-01-18 (Crawled : 14:20) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.46%
H: 0.12%
C: -1.51%
trial
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $42.98 0.0% 7.4M
|
Health Services
| Email alert
Add to watchlist
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.14%
H: 0.81%
C: 0.79%
yescarta ongoing lymphomas t-cell therapy
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published: 2022-12-08 (Crawled : 13:00) - globenewswire.com
JNCE | $1.88 -2.59% -1.85% 0
|
Health Technology
|
| O: 1.82%
H: 1.52%
C: -7.91%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.09%
H: 1.98%
C: 1.82%
medical trial therapeutics phase 1
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
Published: 2022-10-24 (Crawled : 08:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.47%
H: 1.85%
C: 1.31%
biktarvy treatment hiv living
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.